Bone viability determination in human cancellous bone from patients undergoing revision hip arthroplasty.
In December 2000, Sulzer Orthopedics Inc. announced the recall of specific lots of Inter-Op acetabular components as a result of an adverse tissue response to a contaminant on the porous surface of the component. This study was initiated to assess bone viability surrounding the primary and revision components. Twelve patients were placed on a double-tetracycline labeling protocol before revision surgery. Initial and final acetabular reamings were frozen-sectioned using cryostat technology. A mineral apposition rate, preoperative and postoperative radiographs, and Harris Hip Scores were evaluated. The tetracycline data showed that bone viability was not compromised at initial or final reaming levels in this series of patients. Significant improvement was observed in postoperative Harris Hip Scores when compared with preoperative Harris Hip Scores.
Bloebaum
Roy D
RD
Department of Veterans Affairs, Salt Lake City Health Care System, Utah 84148, USA.
Ferguson
Ryan P
RP
Neff
Christian M
CM
Van Gorp
Cornell
C
Woolley
Douglas L
DL
Hofmann
Aaron A
AA
D000077:Acetabulum / Q000473:pathology*; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D019644:Arthroplasty, Replacement, Hip; D005260:Female; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010784:Photomicrography; D012086:Reoperation; D013752:Tetracycline
D000900:Anti-Bacterial Agents; D013752:Tetracycline